Nanotek Biologics Deal Gives Green Cross Route To Russia
This article was originally published in PharmAsia News
Executive Summary
Following its entry into North America and China, Green Cross is set to make inroads into the rapidly growing Russian pharmaceutical market through a strategic partnership with Nanolek to commercialize the South Korean biopharmaceutical company’s biologics.
You may also be interested in...
Korea's Green Cross Sees Earnings Plunge As Flu Fears Wane
SEOUL - As widely expected, vaccine producer Green Cross, one of Korea's leading pharmas, has seen a sharp drop in its sales and net profit during the fourth quarter of last year
Green Cross To Focus On Biobetters As Korean Biosimilar Space Gets Crowded: Bio Korea Conference
SEOUL - Green Cross will turn its attention to "biobetters" in coming years such as its biobetter of Roche's oncology agent Herceptin (trastuzumab) being pursued now, Green Cross CEO Rhee Byung-Geon said during the Bio Korea 2010 conference in Seoul Sept. 1
Green Cross Teams Up With MacroGenics For Bio-better Of Roche's Herceptin
SEOUL - South Korea's Green Cross has signed an agreement with Rockville, Maryland-based MacroGenics to develop and sell the latter's modified anti-breast cancer monoclonal antibody MGAH22 in Korea. MGAH22 is a modified "bio-better" of Roche's oncology agent Herceptin (trastuzumab)